|Articles|August 15, 2013

Probiotic Therapy: Level I Evidence for Which Condition?

Probiotic therapy has level 1 evidence for only one condition-acute infectious diarrhea.

Probiotics have been used to manage all of the conditions below. Which of the following is the only condition with Level I evidence (well-conducted, controlled studies)?

A. Acute infectious diarrhea
B. Irritable bowel syndrome
C. Hepatic encephalopathy
D. Clostridium difficile infection

Please click here for the answer and discussion.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Probiotic Therapy: Level I Evidence for Which Condition?

Related Content

Survey Finds Gaps in US Adult Awareness of HPV, Mpox STI Vaccine Prevention

FDA Approves Ensitrelvir as First Oral COVID-19 Postexposure Prophylaxis Option

New Research Suggests Long COVID Affects 1 in 6 Patients, Doubling Current Estimates

FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection

ASPIRE-CD Highlights Patient-Reported Symptom Gains With Risankizumab in Crohn Disease

Latest CME

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

25th Annual International Congress on the Future of Breast Cancer® East

10th Annual Live Medical Crossfire®: Hematologic Malignancies

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Empire State Hematology & Oncology Society (New York)

Colorado Oncology Society

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

26th Annual International Lung Cancer Congress

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

ADA-SCID Chronicles: A Journey From Screening to Successful Outcomes

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

20th Annual New York Lung Cancers Symposium®

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

ISGIO 2025: Esophageal and Gastric Cancer

ISGIO 2025: Hepatobiliary Cancers

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Optimizing Multidisciplinary Care in TGCT

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Empowering HIV Management: Evidence-Based Prevention and Treatment Strategies

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Community Practice Connections™: 18th Annual New York GU Cancer Congress™

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

SimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Breaking the Demodex Blepharitis Cycle: The Importance of Early Intervention

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Louisiana Oncology Society

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Southern California Psychiatry Conference

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer